| Dr Karrie A Cunningham, MD | |
|
1605 Martin Springs Dr, Suite 320, Rolla, MO 65401-2931 | |
| (573) 458-6359 | |
| (573) 458-6826 |
| Full Name | Dr Karrie A Cunningham |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 30 Years |
| Location | 1605 Martin Springs Dr, Rolla, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285770040 | NPI | - | NPPES |
| 205686405 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 2001002803 (Missouri) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advocates For A Healthy Community Inc | 5395653562 | 34 |
News Archive
It was a controversial move when a health insurer began requiring people who were obese to literally pay the price of not doing anything about their weight - but it worked, a new study finds.
EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.
A new grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health (NIH), will provide funding for University of Miami (UM) College of Engineering researchers to develop a novel bioreactor system that will control mechano-electrochemical environment for tissue growth and also provide on-line monitoring for the properties of engineered tissues.
Virtually all patients who develop myeloma have an asymptomatic disease called monoclonal gammopathy of undetermined significance (MGUS) in the years before the onset of myeloma. The five-year relative survival rate for myeloma is 69% for patients diagnosed with stage I or localized disease, compared with 45% for patients with advanced cancer.
Underage drinking is a concern all over the country. Among American Indian and Alaska Native populations, there are especially serious issues: alcohol use and heavy drinking at an early age increase risks for lifetime alcohol problems, and American Indians and Native Alaskans have reported younger onsets than other groups.
› Verified 2 days ago
| Entity Name | Mercy Clinic Springfield Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245277631 PECOS PAC ID: 7416865845 Enrollment ID: O20031104000060 |
News Archive
It was a controversial move when a health insurer began requiring people who were obese to literally pay the price of not doing anything about their weight - but it worked, a new study finds.
EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.
A new grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health (NIH), will provide funding for University of Miami (UM) College of Engineering researchers to develop a novel bioreactor system that will control mechano-electrochemical environment for tissue growth and also provide on-line monitoring for the properties of engineered tissues.
Virtually all patients who develop myeloma have an asymptomatic disease called monoclonal gammopathy of undetermined significance (MGUS) in the years before the onset of myeloma. The five-year relative survival rate for myeloma is 69% for patients diagnosed with stage I or localized disease, compared with 45% for patients with advanced cancer.
Underage drinking is a concern all over the country. Among American Indian and Alaska Native populations, there are especially serious issues: alcohol use and heavy drinking at an early age increase risks for lifetime alcohol problems, and American Indians and Native Alaskans have reported younger onsets than other groups.
› Verified 2 days ago
| Entity Name | Mercy Clinic Springfield Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972771657 PECOS PAC ID: 7416865845 Enrollment ID: O20031218000354 |
News Archive
It was a controversial move when a health insurer began requiring people who were obese to literally pay the price of not doing anything about their weight - but it worked, a new study finds.
EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.
A new grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health (NIH), will provide funding for University of Miami (UM) College of Engineering researchers to develop a novel bioreactor system that will control mechano-electrochemical environment for tissue growth and also provide on-line monitoring for the properties of engineered tissues.
Virtually all patients who develop myeloma have an asymptomatic disease called monoclonal gammopathy of undetermined significance (MGUS) in the years before the onset of myeloma. The five-year relative survival rate for myeloma is 69% for patients diagnosed with stage I or localized disease, compared with 45% for patients with advanced cancer.
Underage drinking is a concern all over the country. Among American Indian and Alaska Native populations, there are especially serious issues: alcohol use and heavy drinking at an early age increase risks for lifetime alcohol problems, and American Indians and Native Alaskans have reported younger onsets than other groups.
› Verified 2 days ago
| Entity Name | Advocates For A Healthy Community Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558303057 PECOS PAC ID: 5395653562 Enrollment ID: O20041109000631 |
News Archive
It was a controversial move when a health insurer began requiring people who were obese to literally pay the price of not doing anything about their weight - but it worked, a new study finds.
EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.
A new grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health (NIH), will provide funding for University of Miami (UM) College of Engineering researchers to develop a novel bioreactor system that will control mechano-electrochemical environment for tissue growth and also provide on-line monitoring for the properties of engineered tissues.
Virtually all patients who develop myeloma have an asymptomatic disease called monoclonal gammopathy of undetermined significance (MGUS) in the years before the onset of myeloma. The five-year relative survival rate for myeloma is 69% for patients diagnosed with stage I or localized disease, compared with 45% for patients with advanced cancer.
Underage drinking is a concern all over the country. Among American Indian and Alaska Native populations, there are especially serious issues: alcohol use and heavy drinking at an early age increase risks for lifetime alcohol problems, and American Indians and Native Alaskans have reported younger onsets than other groups.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Karrie A Cunningham, MD Po Box 2580, Springfield, MO 65801-2580 Ph: (417) 829-4620 | Dr Karrie A Cunningham, MD 1605 Martin Springs Dr, Suite 320, Rolla, MO 65401-2931 Ph: (573) 458-6359 |
News Archive
It was a controversial move when a health insurer began requiring people who were obese to literally pay the price of not doing anything about their weight - but it worked, a new study finds.
EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.
A new grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health (NIH), will provide funding for University of Miami (UM) College of Engineering researchers to develop a novel bioreactor system that will control mechano-electrochemical environment for tissue growth and also provide on-line monitoring for the properties of engineered tissues.
Virtually all patients who develop myeloma have an asymptomatic disease called monoclonal gammopathy of undetermined significance (MGUS) in the years before the onset of myeloma. The five-year relative survival rate for myeloma is 69% for patients diagnosed with stage I or localized disease, compared with 45% for patients with advanced cancer.
Underage drinking is a concern all over the country. Among American Indian and Alaska Native populations, there are especially serious issues: alcohol use and heavy drinking at an early age increase risks for lifetime alcohol problems, and American Indians and Native Alaskans have reported younger onsets than other groups.
› Verified 2 days ago
Dr. Jenny L Pennycook, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1050 W 10th St, Rolla, MO 65401 Phone: 573-426-2229 Fax: 573-202-2460 | |
Dr. Timothy R. Isakson, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1050 W 10th St, Rolla, MO 65401 Phone: 573-426-2229 Fax: 573-426-4914 | |
Nathan Ratchford, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1050 W 10th St, Rolla, MO 65401 Phone: 573-364-9000 Fax: 573-202-2460 | |
Dr. Max A Lungren, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1605 Martin Springs Dr, Ste 320, Rolla, MO 65401 Phone: 573-458-6359 Fax: 573-458-6826 | |
Wesley Calvin Harden, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1050 W 10th St, Rolla, MO 65401 Phone: 573-364-9000 Fax: 573-202-2460 | |
Dr. James M Davison, D.O. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1050 W 10th St, Rolla, MO 65401 Phone: 573-364-9000 Fax: 573-426-4914 |